These findings are unpublished: These results are brand new and haven't been checked by outside scientists yet. They haven't been published in a journal or even posted as an early draft online. The lab itself labeled its slides "Unpublished."
Everything we know comes from a short, 15-minute talk at a scientific conference on October 1. Our sources are photos of two slides from that talk, a summary on X by scientist Ramon Coronado, a news article from Endpoints News, a post on X by MIT Technology Review reporter Antonio Regalado, and notes from someone who attended. We also draw on Sinclair's April 2026 interview on Impact Theory with Tom Bilyeu, in which he discussed his plans for consumer products.
What was announced
On October 1, at the ARDD aging research meeting at Harvard, Sinclair Lab PhD student Chris Petty shared early results on SL-100, a mix of compounds taken by mouth that aims to make cells act younger. He did not reveal the ingredients, doses, or how they work. The results are still unpublished, but he said a scientific paper is on the way.
According to Endpoints News, which covered the talk, the lab reported results in three systems:
- Lab-grown models of human brain tissue: Treatment with SL-100 for six days changed the activity of thousands of genes, including genes involved in repairing DNA and controlling how cells use their genetic information.
-
Fast-aging mice: A genetic condition causes these mice to age rapidly and live only a few months.
- Weight and physical health: Untreated mice lost about 30% of their weight in a month and became more frail. SL-100-treated mice maintained their weight, with no significant change in frailty.
- Lifespan: Treated mice reportedly lived more than 25% longer on average. One treated mouse was still alive, so results were incomplete. The lifespan findings were not statistically significant.
- Old mice: Treated mice reportedly maintained their physical health over one month, while placebo-treated mice became more frail. No deaths, harmful effects, or tumors were reported during that month.
These findings are still unpublished and have not been reviewed by independent scientists. The lab says it is running bigger mouse studies, testing in larger animals, and developing new versions of the formula. When asked whether anyone had taken SL-100, Petty said not to his knowledge.
On X, journalist Antonio Regalado described the goal as making animals younger while allowing their cells to keep their normal roles. Scientist Ramon Coronado credited Chris Petty and Kelly Rich with the work and said the next steps include publishing the full paper and studying mice that age normally.
Why "reprogramming" matters
In 2006, Shinya Yamanaka showed that activating four specific genes could turn an adult cell back into a stem cell (a cell that can develop into different types of cells). The discovery earned him a Nobel Prize and helped open the door to research on resetting signs of aging in cells.
But there’s a catch: fully resetting a cell also erases its normal role. A liver cell, for example, stops being a liver cell. This can lead to tumors. Researchers developed partial reprogramming, which aims to make cells younger while keeping them doing their usual jobs.
One approach uses gene therapy. Life Biosciences, a company Sinclair co-founded, began its first human trial of ER-100 in 2026. It delivers three reprogramming genes into the eye to treat optic nerve disease. Targeting the eye is easier than delivering treatment throughout the body.
Another approach uses combinations of chemicals to try to produce similar effects. These could potentially be taken as a pill and reach different parts of the body through the bloodstream.
In 2023, Sinclair’s lab published a study showing that six chemical combinations made older human cells appear younger on measures of gene activity after four days, without turning them into stem cells. That study tested cells in a lab, not people or animals. SL-100 is described as a next step in this research, with early testing now happening in animals.
A natural, over-the-counter version?
In a recent podcast interview, Sinclair shared plans for a milder, consumer version of this research. He co-founded a new company, Paradigm 88, to turn molecules from his lab into everyday products.
According to Sinclair:
- The goal: Natural, safe products that reach people sooner and cost less than a prescription drug.
- Possible products: Skin and hair products, and maybe a drink. He didn't share details.
- Less potent: These would be gentler than gene therapy, which is for serious conditions like blindness.
- Early results: The team has three molecules, some of them natural. He said mice given them by mouth did better on tests of strength, memory, and balance after four weeks.
- How they were found: AI may have helped identify them, but he didn't explain how.
- Personal use: Sinclair says he takes some of the natural molecules himself.
- Next step: He says nothing will be released until clinical trials show it works.
Keep in mind: These are claims from an interview, not published research. The molecules, doses, and full mouse results haven't been shared.
The open questions
What’s in it? Neither SL-100's ingredients nor Paradigm 88's molecules have been revealed, so other labs can't check the results. Earlier formulas included a mix of supplements, prescription drugs, and experimental compounds.
Is it safe? Trying to reset cells can increase the risk of tumors if it goes too far. No harmful effects or tumors were reported in the one-month mouse study, but longer studies are needed. A different formula tested by another lab caused harm at high doses and had no effect at low doses.
When will it reach people? Sinclair has discussed plans to test an oral formula through the XPRIZE Healthspan competition, but those plans remain unclear, and no human trial of SL-100 is currently registered. He says Paradigm 88 hopes to release consumer products sooner than a drug could be approved, but he gave no timeline.
The bottom line
SL-100 is still experimental. The early mouse results are worth following, but we don’t yet know whether it can safely make cells throughout the body behave more like younger cells. That will require published results and other labs confirming the findings.
To be clear: SL-100 is an experimental combination of compounds whose ingredients have not been revealed. It is not a supplement or available to buy, and it is unrelated to NAD+ precursors or any Renue By Science product. We’ll update this post when the research is published.
